Cytokinetics Announces Positive Results From SEQUOIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy -December 27, 2023 at 07:31 am EST

Statistically Significant and Clinically Meaningful Increasein Primary Efficacy Endpoint at 24 Weeks of Treatment; Improvement Consistent Across All Prespecified Subgroups Statistically Significant...

Related Keywords

United States ,China ,Fadyi Malik ,Diane Weiser ,Martin Maron ,Tufts University School Of Medicine ,Exchange Commission ,Us Food Drug Administration ,Globenewswire Inc ,Cytokinetics Incorporated Nasdaq ,National Medical Products Administration ,Cytokinetics Incorporated ,Facebook ,Corporate Communications ,Research Development ,Symphony Health ,Clinical Trials Program ,Hypertrophic Cardiomyopathy Center ,Company To Host Conference Call ,Linkedin ,Journal Of The American College Cardiology ,Youtube ,National Principal Investigator ,Statistically Significant ,Clinically Meaningful ,Primary Efficacy Endpoint ,Clinically Meaningful Improvements ,Hall Secondary ,Treatment Interruptions Due ,Host Conference Call ,Webcast Today ,Quantitative Understanding ,Obstruction Impact ,Cytokinetic Executive Vice President ,Medical Center ,University School ,Topline Results ,Broad Phase ,Exercise Capacity ,Assessment Comparing Aficamten ,Cardiac Endpoints In Adults ,Breakthrough Therapy Designation ,Drug Administration ,Medical Products Administration ,Private Securities Litigation Reform Act ,Safe Harbor ,Vice President ,Heart Failure ,Claims Data Dof ,Clinically Diagnosed Hypertrophic Cardiomyopathy ,American Heart Association Task Force ,American College ,Markets ,